Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Roger Echols, MD

Consultant
Infectious Disease Drug Development Consulting

Disclosure(s): Shionogi: Advisor/Consultant, Advisor/Consultant, Advisor/Consultant

Poster(s):

609 - In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
1711 - In Vitro Activity of Cefiderocol Against US Achromobacter spp. and Burkholderia spp. Clinical Isolates from the SENTRY Surveillance Program 2020-2021
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1715 - In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET
1734 - Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
Saturday, October 22, 2022
12:15 PM – 1:30 PM US ET